Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting

References

• Smith CH, Barker JNWN. Psoriasis and its management. BMJ. 2006;19:380–4
   Google Scholar
• Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263–71
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Clark CM, Chalmers RJG, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess. 2000;4:1–125
   PubMedGoogle Scholar
• Nickoloff BJ, Xin H, Nestle FO, Qin J-Z. The cytokine and chemokine network in psoriasis. Clin Dermatol. 2007;25:568–73
   PubMed Web of Science ®Google Scholar
• Fonseca E, Paradela S, Rodríguez Lozano J, Fernández Torres RM. Terapias biológicas para la psoriasis. 2nd ed. Madrid: Fundación do Complexo Hospitalario Universitario A Coruña. Chapter 6, Guías para el tratamiento de la psoriasis en placas moderada-grave con terapias biológicas, 2009. p. 117–36
   Google Scholar
• Haitz KA, Kalb RE. Infliximab in the treatment of psoriasis in patients previously treated with etanercept. J Am Acad Dermatol. 2007;57:120–5
   Google Scholar
• Fernández-Torres RM, Paradela S, Fonseca E. Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA. J Dermatolog Treat. 2014;25:54–6
   PubMed Web of Science ®Google Scholar
• Van Lümig PPM, Lecluse LLA, Driessen RJB, et al. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol. 2010;163:838–46
   PubMed Web of Science ®Google Scholar
• Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66:241–51
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. An assessment of adalimumab efficacy in three phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. Br J Dermatol. 2013;168:374–80
   PubMed Web of Science ®Google Scholar
• Papp K, Menter A, Poulin Y, et al. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. J Eur Acad Dermatol Venereol. 2013;27:634–42
   PubMed Web of Science ®Google Scholar
• Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre. J Eur Acad Dermatol Venereol. 2012;26:1298–303
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164:1091–6
   PubMed Web of Science ®Google Scholar
• Martyn-Simmons CL, Green L, Ash G, et al. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009;23:1394–7
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Bolduc Ch, Poulin Y, et al. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol. 2010;63:228–34
   PubMed Web of Science ®Google Scholar
• Woolf RT, Smith CH, Robertson K, Barker JNWN. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study. Br J Dermatol. 2010;163:889–92
   Google Scholar
• Ortonne J-P, Chimenti S, Reich K, et al. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. J Eur Acad Dermatol Venereol. 2011;25:1012–20
   PubMed Web of Science ®Google Scholar
• Leman J, Burden AD. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. Br J Dermatol. 2012;167:12–20
   PubMed Web of Science ®Google Scholar
• Rivera R, Herranz P, Vanaclocha F. Clinical significance of immunogenicity in biologic therapy. Actas Dermosifiliogr. 2014;105:1–4
   PubMedGoogle Scholar
• Brocq O, Plubel Y, Breuil V, et al. Etanercept-infliximab switch in rheumatoid arthritis: 14 out of 131 patients treated with anti-TNF-alpha. Presse Med. 2002;31:1836–9
   Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010;69:817–21
   PubMed Web of Science ®Google Scholar
• Puig L, Carrascosa JM, Carretero G, et al. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Actas Dermosifiliogr. 2013;104:694–709
   PubMedGoogle Scholar
• Puig L, de la Cueva P, Linares M, et al. Expert report on psoriasis: Spanish dermatologists' opinions on the use of biologic agents to manage moderate to severe psoriasis in adults. Actas Dermosifiliogr. 2013;104:400–8
   Google Scholar
• Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:987–1019
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50
   PubMed Web of Science ®Google Scholar
• Papoutsaki M, Chimenti M-S, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open label study in 30 patients previously treated with other biologics. J Am Acad Dermatol. 2007;57:269–75
   PubMed Web of Science ®Google Scholar
• Ryan C, Kirby B, Collins P, Rogers S. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Clin Exp Dermatol. 2009;34:784–8
   PubMed Web of Science ®Google Scholar
• Lecluse LLA, de Groot M, Bos JD, Spuls PI. Experience with biologics for psoriasis in daily practice: switching is worth a try. Br J Dermatol. 2009;161:948–51
   PubMed Web of Science ®Google Scholar
• Strober BE, Poulin Y, Kerdel FA, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011;64:671–81
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11(Suppl. 1):S1. doi: 10.1186/ar2666
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis. 2007;66:849–51
   PubMed Web of Science ®Google Scholar
• De Simone C, Amerio P, Amoruso G, et al. Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? Expert Opin Biol Ther. 2013;13:1673–82
   PubMed Web of Science ®Google Scholar
• Palau N, Julià A, Ferrándiz C, et al. Genome-wide transcriptional analysis of T cell activation reveals differential gene expression associated with psoriasis. BMC Genomics. 2013;14:825
   Google Scholar
• Driessen RJB, Boezeman JB, van de Kerkhof PCM, de Jong EMGJ. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol. 2009;160:670–5
   PubMed Web of Science ®Google Scholar
• Blom M, Kievit W, Fransen J, et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol. 2009;36:2171–7
   PubMed Web of Science ®Google Scholar
• Sterry W, van de Kerkhof P. Is ‘class effect’ relevant when assessing the benefit/risk profile of a biologic agent? J Eur Acad Dermatol Venereol. 2012;26:9–16
   Google Scholar